Therapeutic Drug Monitoring to Spike to $2.69 Billion by 2019
Dublin, Sept. 26, 2013 (GLOBE NEWSWIRE) -- Research and Markets
announced the addition of the "Therapeutic Drug Monitoring Markets" report to
Therapeutic drug monitoring can be categorized into seven main modalities:
antiepileptics, antiarrhythmics, antibiotics, antineoplastics,
bronchodilators, immunosuppressives and HIV/AIDS drugs. The global therapeutic
drug monitoring market is dominated by eight major suppliers that account for
a combined 88.3% of the global market. The U.S. market is expected to grow to
$1.84 billion by 2019 at a CAGR of 12.6%.
The "Therapeutic Drug Monitoring" report covers:
*High Pressure Liquid Chromatography (HPLC)
*Gas Chromatography/Mass Spectrometry
*Liquid Chromatography/Mass Spectrometry
*Enzyme Multiplied Immunoassay Technique
*Cloned Enzyme Donor Immunoassays
*Fluorescence Polarization Immunoassays
*Lateral Flow Immunoassays
*Particle Enhanced Turbidimetric Inhibition Immunoassays
*Affinity Chrome Mediated Immunoassays
Detailed charts with sales forecasts and marketshare data are included.
The "Therapeutic Drug Monitoring" report examines companies manufacturing
therapeutic drug monitoring equipment and supplies in the world. Companies
*Alere/ Inverness Medical Innovations
For more information visit
Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Research and Markets logo
Press spacebar to pause and continue. Press esc to stop.